Recent Advances Lead University of Minnesota to Attempt New Therapy for Tay-Sachs Disease
A 22-month-old Tay-Sachs patient travels from California to receive new drug combination and umbilical cord blood transplant at the University of Minnesota.
University of Minnesota doctors were confident in their ability to treat the young Tay-Sachs patient from California. And, Children’s Cancer Research Fund was proud to contribute funds to help develop this innovative protocol that has the potential to change treatment and outcomes for future children diagnosed with Tay-Sachs.
Krystie is being watched closely since her transplant more than six-months ago. Dr. Paul Orchard, one of her primary physcians, remains optimistic about her future, but questions still remain. Read more about Krystie's Story.
Continued Focus on Rare Genetic and Metabolic Diseases
Using methods that are typically already being investigated for childhood cancer treatments, Dr. Orchard leads a team of talented researchers in an effort to change the often fatal outcome of many genetic or metabolic storage diseases such as Tay-Sachs, Adrenoleukodystrophy and Krabbe Disease.
A portion of Children's Cancer Research Fund's Research Strategic Plan supports studies into innovative treatments for these rare but devastating diseases in children.